anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although most of the prostate cancers (PCas) are currently being diagnosed at early stage, at present, 30% of men are diagnosed with primarily metastatic disease. The need for better diagnostic methods is, therefore, warranted. Recent studies have shown that an alternative pathway using multiparametric (mpMRI) or biparametric (bpMRI) magnetic resonance imaging as a triage test reduces unnecessary biopsies, decreases the detection of clinically non-significant PCa (non-SPCa), and improves the detection of clinically significant PCa (CSPCa). In addition, based on these trials, also EAU guideline was updated to recommend that all men should undergo pre-biopsy mpMRI. However, shortcoming of the approach is the recommendation to biopsy all men post-MRI even if there is no lesion seen in MRI, ie. risk of PCa is very low. Therefore, the primary objective of this randomised controlled trial is to compare if there is a difference between significant cancer detection rate in men undergoing prostate biopsies after MRI scan compared to men undergoing post-MRI prostate biopsies only after a shared decision-making based on prostate cancer risk estimation.

The trial will enrol 600 patients from four hospital districts: Varsinais-Suomi, Satakunta, Pirkanmaa and Keski-Suomi. Key inclusion criteria are suspicion of prostate cancer based on elevated PSA and/or abnormal digital rectal examination. Men with previous PCa diagnosis and contraindications for MRI are excluded. The primary outcome measure is the comparison of the proportion of men with CSPCa (Gleason 4+3 prostate cancer or higher) between the control and intervention arms at baseline.

Using PSA as strata, eligible men are randomised 1:1 in two groups. After randomisation MRI examination is performed and interpreted by one experienced uro-radiologist using Likert and PI-RADS2.1 classifications. In control arm in all men prostate biopsies are performed after MRI whereas in intervention arm prostate biopsies are performed only after a shared decision-making between urologist and the patient and the discussion is based on risk estimation. Men with negative biopsies or with no biopsies performed are all assigned for five-year follow-up with semi-annual PSA. Long-term follow-up based on health records and national registries is performed for additional 15 years for all patients.
Atorvastatin calcium is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP). Atorvastatin calcium plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. Table 2 includes a list of drugs that may increase exposure to atorvastatin calcium and may increase the risk of myopathy and rhabdomyolysis when used concomitantly and instructions for preventing or managing them [see Error! Hyperlink reference not valid. and Error! Hyperlink reference not valid.]. 

Table 2: Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with Atorvastatin Calcium
PROBLEM TO BE SOLVED: To obtain a crosslinked polymer comprising the crosslinking reaction product of a specific thermoplastic resin by the irradiation of active energy light, capable of melting at a relatively low temperature, having proper viscoelasticity at a melting time and at a solidifying time, respectively, and therefore useful as a sheet material for radiation therapies, plaster cast therapies, etc. SOLUTION: This crosslinked polymer is obtained by crosslinking a thermoplastic resin having a melting point of 40-80 deg.C [e.g. a resin comprising 100 pts.wt. of polycaprolactone resin, poly trans-isoprene resin or an ethylenic copolymer resin and 0.1-30 pts.wt. of a multifunctional acrylic monomer or a multifunctional allyl monomer] by the irradiation of active energy light. The thermoplastic resin as the raw material is preferably the resin having an average mol.wt. of 10000-300000, especially 40000-200000.
PURPOSE:To obtain modified powder eliminated its surface activity and having improved surface characteristics such as hydrophobic nature, etc., while keeping the original properties of the powder, by contacting powder having active points on the surface with vapor of a specific silicone compound. CONSTITUTION:Powder having active points on its surface is made to contact with vapor of a silicone compound of formula (R<1>-R<6> are H or 1-10C hydrocarbon group which may be substituted with halogen; R<1>, R<2> and R<3> are not H at the same time; a and b are 0 or integer of >=1; c is 0 or 2; when c is 0, a+b is integer of >=3). The silicone compound is polymerized on the whole surface of the powder by the contacting process to produce the objective powder having a silicone polymer coating film supported on the whole surface. The contacting process is preferably carried out in a closed vessel at <=100 deg.C under a pressure of <=100mmHg. The compound of formula is e.g. 1,1,1,2,3,4,4,4- octamethyltetrasiloxane, etc.
Post treatment failure could be treated by two options including orthograde retreatment and apical surgery . In a previous study, orthograde retreatments presented a success rate of 81 % classified as healed and 93 % as no symptoms and fully functional. In a systematic review, it has also been concluded that endodontic surgery offers more favorable initial success but orthograde retreatment yields to a better long-term outcome . Although early results of single-visit treatments are contradictory ; Completing the treatment in a single appointment reduces the treatment time and cost, decreases micro leakage risk and avoids recontamination of root canals between appointments in multiple-visit treatments . Again, reviewing the literature concerning primary treatment showed that, no significant differences were observed in healing of periapical radiolucency between teeth treated in single-visit and those treated in two-visits. Even, after using calcium hydroxide for four weeks . The presence of a positive bacterial culture at the time of filling did not influence the outcome of treatment .

Thorough online search revealed that, few studies are found concerning post- operative pain after single visit retreatment . The present study is designed to compare the effects of single-visit and two-visit root canal treatments on postoperative pain in retreatment cases. The primary outcome measure of this study is proposed to be whether single-visit root canal retreatment influenced the occurrence of postoperative pain as compared to two-visit treatment.
A method is provided for identifying a number of variants of concern of a reference disease associated immunogen. The method uses a language model to perform inference on data representing each of a plurality of variants and data representing the reference immunogen. For each of the plurality of variants and the reference immunogen, a characteristic vector is derived from an output feature map of a hidden layer of the language model. For each of the plurality of variants, a measure of distance is generated for the variant that includes calculating a measure of distance between the characteristic vector of the variant and the characteristic vector of the reference immunogen. A semantic change score is calculated for each variant based on the generated measure of distance for that variant. A variant of the reference immunogen is selected based, at least in part, on the generated the semantic change scores.
Evaluations: The subjects will be included in the participating centers following a suicide attempt (SA). After checking of the criteria, information and signature of the study consent, the subjects will be randomized in one of the 2 groups (ALGOS versus Control). A fax of inclusion will be sent to the centralized research team of the Clinical Investigation Center (CIC) of Lille. All the subjects included will be then evaluated at the 6th month and 13th month after the SA, during a phone call. The final evaluation will be carried out in the current of the 13th month, so as to avoid a recontact at the time of the period birthday, too charged affectively at the majority with the patients. This phone call, personal, will be carried out by an trained psychologist. A mail preventing the subject of the call will be addressed approximately 10 days before. During the evaluations at the 6th month and 13th month, the number of suicidal repetitions will be reported, consumption of care since inclusion will be noted, the scale of suicidal ideation of Beck assessed, and a psychopathological evaluation carried out (Mini International Neuropsychiatric Interview DSM IV).
A pharmaceutical composition containing cariprazine, a preparation method and an application thereof are provided. The pharmaceutical composition contains cariprazine pamoate solid particles. A particle size of the cariprazine solid particles has a Dv(10) less than or equal to 30 microns, a Dv(50) less than or equal to 50 microns, and a Dv(90) less than or equal to 100 microns. When being used, the pharmaceutical composition containing cariprazine is an aqueous suspension and, the concentration of the free base of cariprazine is moderate. A long-term effect can be achieved upon injection of a certain administration volume of the pharmaceutical composition, thereby reducing the frequency of medication while increasing patient medication compliance. Furthermore, the pharmaceutical composition has a high bioavailability and has promising marketing prospects.
Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
PURPOSE:To obtain the subject hydrolyzate, having a high nutritive value and useful as an enteric nutriment, a medical diet, a nourishing enriched food, a nourishing beverage, etc., without any unpleasant taste by adding and mixing a milk protein with a raw material protein except the milk protein and carrying out the enzymic hydrolysis. CONSTITUTION:A protein except a milk protein is used as a raw material to produce an enzymic hydrolyzate. In the process, the raw material protein such as dried albumen and separated soybean protein is dissolved in water and an aqueous solution of the milk protein such as skim milk powder is then added and mixed therewith. The resultant mixture is uniformized and then sterilized at 110 deg.C for 5min and a proteolytic enzyme such as a protease is subsequently added thereto. Enzymic reaction is carried out at 50 deg.C for 14hr and the prepared reactional solution is then heated at 90 deg.C for 15min to inactivate the enzyme. The produced insoluble substance is subsequently centrifuged to lyophilize the supernatant. Thereby, the objective protein hydrolyzate useful as a nitrogen source such a an enteric nutriment, a medical diet, a nourishing enriched food or a nourishing beverage due to its high nutritive value without any unpleasant taste is obtained.
The CONVINCE study, recently published in the New England Journal of Medicine, reveals a groundbreaking 23% reduction in the relative risk of all-cause mortality among end-stage kidney patients undergoing high convective volume hemodiafiltration. This significant finding challenges the conventional use of high-flux hemodialysis and offers hope for improving outcomes in chronic kidney disease patients. While some controversies surround the study's findings, including concerns about generalizability and the causes of death, it is essential to acknowledge the study's design and its main outcomes. The CONVINCE study, part of the HORIZON 2020 project, enrolled 1360 patients and demonstrated the superiority of hemodiafiltration in reducing all-cause mortality overall, as well as in specific patient subgroups (elderly, short vintage, non-diabetic, and those without cardiac issues). Interestingly, it was shown that hemodiafiltration had a protective effect against infection, including COVID-19. Future research will address sustainability, dose scaling effects, identification of subgroups especially likely to benefit and cost-effectiveness. However, for now, the findings strongly support a broader adoption of hemodiafiltration in renal replacement therapy, marking a significant advancement in the field.
The enteric nervous system (ENS) regulates numerous functional and immunological attributes of the gastrointestinal tract. Alterations in ENS cell function have been linked to intestinal outcomes in various metabolic, intestinal, and neurological disorders. Chronic kidney disease (CKD) is associated with a challenging intestinal environment due to gut dysbiosis, which further affects patient quality of life. Although the gut-related repercussions of CKD have been thoroughly investigated, the involvement of the ENS in this puzzle remains unclear. ENS cell dysfunction, such as glial reactivity and alterations in cholinergic signaling in the small intestine and colon, in CKD are associated with a wide range of intestinal pathways and responses in affected patients. This review discusses how the ENS is affected in CKD and how it is involved in gut-related outcomes, including intestinal permeability, inflammation, oxidative stress, and dysmotility.
The invention discloses application of Houttuynoid D in preparation of an antidepressant drug. The invention provides the use of Houttuynoid D in the antidepressant drug. The Houttuynoid D disclosed by the invention can be used as the drug for preventing or treating depression. The use of the Houttuynoid D disclosed by the invention in the preparation of the antidepressant drug is firstly disclosed. The framework type is a brand-new framework type and has an unexpected strong effect of restraining the bacterial activity, and so the Houttuynoid D is impossibly reveled by other compounds, and has outstanding substantial characteristics. Meanwhile, the Houttuynoid D has significant progress in antidepressant drug.
OBJECTIVES: I. Determine the safety and maximum tolerated dose level of the vaccine consisting of MAGE-3 or Melan-A (human tumor antigen genes) peptide-pulsed autologous peripheral blood mononuclear cells plus interleukin-12. II. Determine if the procedure results in successful immunization. III. Assess the response of the tumor to the vaccine.

OUTLINE: This is an open label, nonrandomized, single institution study. Patients receive 3 initial courses of treatment consisting of 21 days each. Treatment consists of an immunization with MAGE-3 or Melan-A peptide-loaded autologous PBMC and interleukin-12 (IL-12) on the first day, IL-12 on days 3 and 5, and 16 days of rest. The first cohort is not administered IL-12 and the next cohorts are given escalating doses of IL-12. The Phase II dose will be one dose level below the MTD. Patients who have a tumor remission response or stable disease may continue treatment for up to one year. Phase I completed as of 04/1999. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.
A method of preparing a bone graft. An osteoconductive matrix is placed in a receptacle. Bone marrow aspirate is provided that includes plasma, progenitor cells, hematopoietic cells, endothelial cells, red blood cells, white blood cells, platelets, bone, cartilage, thrombus or combinations thereof. The bone marrow aspirate is passed through the receptacle. At least a portion of bone marrow aspirate is retained in the receptacle. The portion of the bone marrow aspirate retained in the receptacle becomes associated with the osteoconductive matrix to form the bone graft.
The invention relates to a fumosorosedge A with the functions of resisting bacteria, scavenging free radicals and inhibiting tyrosinase activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The fumosoroside A is light yellowish brown powder, and has a bacteriostasis zone of 18.6 mm for Escherichia coli and 21.3 mm for Streptomyces albus at a concentration of 200 mg/mL. Half-scavenging concentration (DC) of P-diphenylpicrylphenylhydrazine radical (DPPH)  50  ) The method comprises the following steps: 260. Mu.g/mL. Half Inhibition Concentration (IC) of tyrosinase  50  ) The method comprises the following steps: 79 μg/mL. The fumosoroseside A can be obtained by culturing fumosoroseus cordyceps, and then extracting and separating. The fumosoroseside A can be used for preparing antibacterial agents, free radical scavengers and tyrosinase inhibitors with antibacterial and antifungal effects, and has the potential of preparing health-care products with the functions of resisting oxidation, whitening and resisting aging. The preparation method of the invention adopts microbial fermentation production, is environment-friendly, is not influenced by natural environment and resources, and is easy to realize industrialized, automatic and continuous production.
People with severe intellectual disabilities (ID) could have difficulty expressing their stress which may complicate timely responses from caregivers. The present study proposes an automatic stress detection system that can work in real-time. The system uses wearable sensors that record physiological signals in combination with machine learning to detect physiological changes related to stress. Four experiments were conducted to assess if the system could detect stress in people with and without ID. Three experiments were conducted with people without ID (n = 14, n = 18, and n = 48), and one observational study was done with people with ID (n = 12). To analyze if the system could detect stress, the performance of random, general, and personalized models was evaluated. The mixed ANOVA found a significant effect for model type, F(2, 134) = 116.50, p < .001. Additionally, the post-hoc t-tests found that the personalized model for the group with ID performed better than the random model, t(11) = 9.05, p < .001. The findings suggest that the personalized model can detect stress in people with and without ID. A larger-scale study is required to validate the system for people with ID.
Pregnancy Category C.

Animal reproduction studies have not been conducted with niacin or with NIASPAN. It is also not known whether niacin at doses typically used for lipid disorders can cause fetal harm when administered to pregnant women or whether it can affect reproductive capacity. If a woman receiving niacin for primary hyperlipidemia becomes pregnant, the drug should be discontinued. If a woman being treated with niacin for hypertriglyceridemia conceives, the benefits and risks of continued therapy should be assessed on an individual basis.

All statins are contraindicated in pregnant and nursing women. When NIASPAN is administered with a statin in a woman of childbearing potential, refer to the pregnancy category and product labeling for the statin.
PURPOSE:To obtain the titled preparation stable at room temperature, injectable as an aqueous solution, by adding a substance selected from a thiol compound, a high polymer compound and a water-soluble salt of deoxycholic acid to a prostaglandin E, and lyophilizing the blend. CONSTITUTION:A prostaglandin E is blended with a substance selected from a thiol compound (e.g., gluthathione, cysteine, etc.), a high polymer compound (e.g., dextran, dextrin, PVP, etc.), and a water-soluble salt of deoxycholic acid and an alkali metal, arginine, or lysine) in an amount not to show medicinal effect, and lyophilized. Preferably an amount of the thiol compound per vial is 1-20mg, an amount of the high polymer compound is 5-250mg, and an amount of the water-soluble salt of deoxycholic acid is 5-100mg. The PGE having wide pharmaceutical action such as contraction of the womb, hypotensive action, remedying and preventing action on ulcer of digestive organs, vasodilating action, etc., can be preserved stably at room temperature for a long period.
BACKGROUND: The renal sympathetic nervous system modulates systemic blood pressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF). We investigated the effects of renal sympathetic denervation performed at early or late stages of HFpEF progression.
METHODS AND RESULTS: Male ZSF1 obese rats were subjected to radiofrequency renal denervation (RF-RDN) or sham procedure at either 8 weeks or 20 weeks of age and assessed for cardiovascular function, exercise capacity, and cardiorenal fibrosis. Renal norepinephrine and renal nerve tyrosine hydroxylase staining were performed to quantify denervation following RF-RDN. In addition, renal injury, oxidative stress, inflammation, and profibrotic biomarkers were evaluated to determine pathways associated with RDN. RF-RDN significantly reduced renal norepinephrine and tyrosine hydroxylase content in both study cohorts. RF-RDN therapy performed at 8 weeks of age attenuated cardiac dysfunction, reduced cardiorenal fibrosis, and improved endothelial-dependent vascular reactivity. These improvements were associated with reductions in renal injury markers, expression of renal NLR family pyrin domain containing 3/interleukin 1β, and expression of profibrotic mediators. RF-RDN failed to exert beneficial effects when administered in the 20-week-old HFpEF cohort.
CONCLUSIONS: Our data demonstrate that early RF-RDN therapy protects against HFpEF disease progression in part due to the attenuation of renal fibrosis and inflammation. In contrast, the renoprotective and left ventricular functional improvements were lost when RF-RDN was performed in later HFpEF progression. These results suggest that RDN may be a viable treatment option for HFpEF during the early stages of this systemic inflammatory disease.
Virtual reality (VR) is a technological rehabilitation tool that allows the user to experience the interaction with a computer-generated environment. It may provide some advantages over conventional care: it allows the simulation of realistic environments and patients feel more motivated by this kind of virtual environment. VR constitutes an enriched environment with augmented multiple sensory feedbacks (auditory, visual, tactile VR enriched environment) that has already shown some efficiency in reducing chronic pain. There is mounting evidence from acute pain conditions, such as wound care, that VR could play a role as an additional treatment method to relieve pain A possible explanation for its mechanism of action is provided by "the gate-theory of attention". VR reduces the perception of pain by diverting attention away from the pain. Most children experience pain and fear when receiving a medical treatment; two feelings which are closely related and affecting one another. Moreover, children often describe procedures involving needles as the most stressful portion of the hospital experience. Children who have been implanted with an intrathecal baclofen (ITB) pump, need to come to the hospital for a refill approximately every 3 months, depending on the exact dose. During the refill, the physician places a needle directly into the reservoir to refill the pump. To alleviate the pain and fear with these refill procedures, it is hypothesized that VR could alleviate pain and make these refills more feasible. Therefore, the aim of this study is to evaluate whether VR is reducing pain during a refill procedure, in children receiving intrathecal drug delivery compared to usual care.